Polaryx Therapeutics, Inc.

PLYX Nasdaq SEC CIK 2075320
Follow Polaryx Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.3M −132.7% vs same quarter last year
EPS, diluted −$0.07 −133.3% vs same quarter last year
Operating cash flow −$3.1M −249.7% vs same quarter last year
Operating income −$3.3M −241.7% vs same quarter last year
Net income by quarter
−$5.1M
−$1M
−$1.4M
−$1.5M
−$2.5M
−$1.4M
−$3.3M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing